Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I bought in on a tip on this one.
Looked in profits on the other one, and am just holding a core position. We have time on that one. But my bet is that one will see teens this year. I have a friendly gum bet going with someone who I know is clearly out! No puts. Lol. :)
My money is on tpiv and onsc but I got in those at dream prices.
Lots of other picks, but those were my diamond in the rough picks that are paying off. Haven't sold. :)
Hey Rk, we shall see. i may have to wait for my "CVR" for a good profit. i still have questions that i haven't found answers for in the filings. hard to do a thorough reading when at work.
Our other stock is doing very well as is my hinted stock :)
take care.
giant gaps like that don't take off most of the time.
Hi Map, easy profit, smart move. :)
The non stop selling could be a sign of something
Hi Rk, a day late and a few dollars short it seems. i just read the companies latest report and was planning on buying today but did not expect to be buying 16% higher than yesterdays close. looks like a pretty good deal to me so i bought some today anyway.
GL
another filing just out- INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders of DARA BioSciences, Inc. of Commencement of an Investigation Reg...
http://ih.advfn.com/p.php?pid=nmona&article=67155953
Maybe this pr ? , http://secfilings.nasdaq.com/filingFrameset.asp?FileName=0001214659-15-002583%2Etxt&FilePath=%5C2015%5C03%5C27%5C&CoName=DARA+BIOSCIENCES%2C+INC%2E&FormType=S-3&RcvdDate=3%2F27%2F2015&pdf=
but it dosn't matter imo. the deal is done and shareholders will get up to $29m.
http://ih.advfn.com/p.php?pid=nmona&article=67150275
It just makes no sense to dump all these shares in the low .90 when you get 1.20. But there is massive selling into this. Like someone knows something we dont....
Is that matter?,DARA sold for $24m.SHAREHOLDERS WILL GET UP TO $29M
Who in their right mind is dumping these shares under value????
Right on. I wont sell today. Maybe 2-3$ in the near future. Gl
they're gonna want to see at least the $2+ price per share to make it worth their while
Actually DARA 's value is US$29.7 million. Oxford, UK, 4 June 2015 – Midatech (AIM: MTPH), the international specialty pharmaceutical company with a diversified portfolio of high-value products in development, today announces the proposed acquisition of DARA BioSciences, Inc. (“DARA”) (NASDAQ: DARA), an oncology supportive care pharmaceutical company (the “Acquisition”). Midatech will issue approximately 5.4 million new ordinary shares in exchange for the outstanding shares of DARA, representing an initial consideration of approximately US$24.0 million (£15.8 million) based on a Midatech share price of 291 pence, subject to certain adjustments. In addition, DARA shareholders will receive contingent value rights (“CVRs”) to conditional cash payments of a maximum of US$5.7 million (£3.8 million) in aggregate based on the performance of certain DARA products, representing a total consideration of up to approximately US$29.7 million (£19.5 million).
BOOOOOOM. Acquisition at 50% higher value (or $1.2 PPS)
http://ih.advfn.com/p.php?pid=nmona&article=67150275
The buyer offer $1.2($24m) for DARA,that means the company worth much more than that. they wanna see at least 2+ PPS.
New Presentation just Uploaded: Jun 1, 2015 the Website, the market potential is HUGE.imo
http://content.stockpr.com/darabiosciences/media/c976ca328111dbd3413b3d863250eb19.pdf
I think it goes higher, maybe a sweetened offer will be needed to get the deal done
Thanks for the alert on this the other day Ash! Congrats!! Took some in pre market. See how the volatility plays out.
Shoulda listened to you A LOT sooner lol
Thanks Ash for getting me in. Looks like they undersold it, but at least we're up. :)
.80-1.10 not bad ;)
Thieves to let this go for 1.20. Anyway, my 20K @0.78 will give me around 10 grand profit. Not bad for holding a week ??
thats a big plus for us:),looks like some interest after hours.
ihub usually only catches on to nasdaq/amex bios once they've already ran.
NP.the New Presentation confirmed every number i posted here..im not a bio expert but surly know what is solid and what is not.and DARA is a very solid NASDAQ company since Q1 out 3 weeks ago (ihub still dosn't knows about her) with great developments(and more to come) and maybe the cheapest nasdaq bio company right now.(19m o/s,15m cap,11m net assets,10m cash).
will be fun when news hits,thats for sure.
thanks.
i've been on board since .70s and adding on breakout.
New Presentation just Uploaded: Jun 1, 2015 the Website,
Cash balance of $9.9 million as of March 31, 2015 (exactly as i mentioned before),a Record Sales Growth (Q1 15 vs Q1 14) as well.
16m cap for a NASDAQ company with $11m net assets+almost $10m cash(increased 50%) ,is a screaming buy. you will find out when news hits.
http://content.stockpr.com/darabiosciences/media/c976ca328111dbd3413b3d863250eb19.pdf
Totally agree. Even now this is so undervalued. 11m net assets,almost 10m cash vs market cap of only 16m. Great SS as well. A very very solid NASDAQ company here.
DARA
DARA is under valued now its up to Management to release the value...when they do thats when a major re-price will come 2s
This is the most cheapest NASDAQ biotech company but very solid ( I posted numbers.check them out).reversal just started since Q1 out.
Chart Looks like kabooom soon imo. Got 20K @0.78. GLA
$DARA starting to flag here
I like this as long as it trades and holds over .70c
here why recent weeks reversal :"Our first quarter results reflect a solid start for the year, as our product portfolio continues to perform well,"
"We are excited about the acquisition of Oravig® in March, which provides us with another valuable supportive care product for our portfolio. We expect to quickly leverage the significant market opportunity for Oravig in both the oncology and broader markets. Pre-launch planning activities are well underway and we are scheduled to introduce Oravig back to the market in the fourth quarter."
http://www.darabio.com/media-center/press-releases?detail=646
Ladenburg Thalmann Financial Services, Inc.($600M+CO.) DARA -Analyst Coverage
http://ir.darabio.com/analyst-coverage
http://www.otcmarkets.com/stock/LTS/profile
Insiders buying, Top Institutional Holders:
Holder Shares % Out Value* Reported
BlackRock Institutional Trust Company, N.A. 991,911 5.02 724,095 Mar 31, 2015
Renaissance Technologies, LLC 144,900 0.73 105,777 Mar 31, 2015
Sabby Management, LLC 117,370 0.59 85,680 Mar 31, 2015
Vanguard Group, Inc. (The) 90,781 0.46 66,270 Mar 31, 2015
KCG Holdings, Inc. 45,392 0.23 33,136 Mar 31, 2015
Goldman Sachs Group, Inc. 41,845 0.21 30,546 Mar 31, 2015
Susquehanna International Group, LLP 36,853 0.19 26,902 Mar 31, 2015
Geode Capital Management, LLC 31,100 0.16 22,703 Mar 31, 2015
Citadel Advisors LLC 24,798 0.13 18,102 Mar 31, 2015
Nomura Holdings Inc. 18,180 0.09 13,271 Mar 31, 2015
Cash increased almost 50%, Cash and cash equivalents at end of period $ 9,852,573
Total assets $ 14,758,019
Total liabilities $ 3,606,718
great shape. market value only $15m vs $20m (cash + Net Assets)
Looking great bud!
Im not a bio expert but i can tell you.DARA financials very solid.only 19m o/s,15m cap
NET ASSETS-more than $10m. Assets/Debt ratio even great,more than 4,that's means on the right news PPS could be move fast.
just coming from 52 wk .low. looks like a great buying opp.
volume increased 6 times on Friday. what kind of news expected here?
thanks
$2.00's will just be getting started. $5 is likely with the news of partnership. higher as news of positive results of tests...surf the coming tide.
DARA still flying under the radar....I'm bullish this ticker and i think a double is very possible if not more with the right news flow...2.00s
Innovations and BOD pay cheques... That all what matters :)
$DARA getting closer.. lots of biotech momentum out there
$DARA getting closer.. lots of biotech momentum out there
Dara i took 55,000 share position myself the last days. Look at what some of these small bios have been doing. pbmd was 40c not long ago.Also gtxi also left for dead just did a double in a couple trading days.Dara just needs to get that news flow and some 5-10 million share days in volume to the upside and this flys
Smart of me to load thousands yesterday at .68 pennies. That cat Mitch has been spot on with news and so I will continue to follow his lead.
Haha , smart money, The cat Mitch knows it all?
Added more, based on sound financials and a blow out Q2 thats building up. Fed news likely regarding KRN5500, smart money is stock piling the shares away.
Followers
|
118
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
6805
|
Created
|
10/30/06
|
Type
|
Free
|
Moderators |
Soltamox® (tamoxifen citrate) is the only oral liquid formulation of tamoxifen available in the US and is an important option for breast cancer patients who have difficulty adhering to tablet therapy.
Tamoxifen is widely used to treat estrogen-receptor positive breast cancer and patients at high risk for the disease. In the US, over 230,000 new cases of breast cancer are diagnosed each year, and over 1.8 million prescriptions are written for tamoxifen.
While tamoxifen is an effective therapy, it must be taken for up to five years in order for the full benefits to be realized. A number of well designed studies indicate long term adherence to treatment is less than optimal, with up to 50% of patients discontinuing treatment earlier than they should. To address the need for improved adherence, Soltamox was developed to offer breast cancer patients a new option for daily compliance. Patients who may benefit from Soltamox include those who prefer a liquid versus a pill, patients who have swallowing difficulties and patients who may benefit from a change in formulation. For patients with intolerance to gluten or lactose, Soltamox is both gluten and lactose free.
Soltamox is available as a sugar-free oral solution (equivalent to 10mg/5mL). Each bottle contains 150 mL.
DARA has an exclusive license to market Soltamox® in the U.S. from Rosemont Pharmaceuticals, LTD, a UK-based manufacturer and marketer of oral liquid medicines. Soltamox is patent-protected through 2018
For additional information on Soltamox visit: http://soltamox.com/
For important safety information and warnings please click here.
Gelclair® is a bioadherent oral rinse gel indicated for the management and relief of pain associated with oral mucositis, a condition characterized by erythema (redness, swelling) and painful oral lesions. Oral mucositis frequently occurs in cancer patients, a result of chemotherapy or radiation therapy. It is estimated over 400,000 cases of therapy-induced oral mucositis occur annually, and is seen most often in patients receiving radiation therapy for head and neck cancer, and patients receiving high-dose chemotherapy conditioning prior to hematopoietic stem cell transplantation (HSCT). Left untreated, oral mucositis can lead to intense pain, impact patients’ ability to swallow food and liquids, cause weight loss, delay cancer treatment and increase treatment costs.
Gelclair is a unique oral gel whose key ingredients are polyvinlypyrrolidone (PVP) and sodium hyaluronate (Hyaluronic Acid). Gelclair is easily applied, via an oral rinse, and provides rapid and effective relief from pain, by creating a protective coating over the oral mucosa. This coating, or barrier, alleviates irritation of exposed nerves in the ulcer areas, as well as moisturizing the tissue. Patients experience relief from pain and are also able to eat and drink more easily.
Gelclair is the most clinically studied oral gel in the US, with studies supporting:
For additional information on Gelclair visit: http://gelclair.com/
DARA obtained a license from Innocutis Holdings for the exclusive rights to market Bionect® (hyaluronic acid sodium salt, 0.2%) in both radiation and oncology. Bionect treats burns and other skin changes (radiation dermatitis) associated with radiation treatment. Bionect is a patent-protected low-molecular-weight hyaluronic acid (LMW-HA) cream or gel which penetrates to the dermal layer. In a randomized double-blind placebo-controlled study of 134 radiation patients, the low molecular weight hyaluronic acid (LMW-HA) formulation Bionect cream was shown to significantly reduce the incidence of high-grade skin reactions, delay their onset & reduce their severity. (Ligouri V. et al, Radioth Oncol. 1997; 2:155-161)
For additional information on Bionect visit: http://bionect.com/
KRN5500 is a non-narcotic, non-opioid, intravenously administered new chemical entity (NCE) in development for painful chronic chemotherapy induced peripheral neuropathy (CCIPN). DARA is currently seeking a development and commercialization partner for KRN5500.
KRN5500 has successfully completed a Phase 2a proof of concept study in patients with end-stage cancer, meeting its primary endpoint of pain reduction relative to placebo (p = 0.03). Safety results from the study included clinically important gastrointestinal side effects, but no other major safety concerns were found at doses that were much lower than those studied in earlier Phase 1 oncology trials completed under a National Cancer Institute (NCI) investigational new drug (IND) application for treatment of solid tumors.
In 2011, the U.S. Food and Drug Administration (FDA) designated KRN5500 a Fast Track Drug Development Program. The Fast Track initiative is designed to facilitate development and expedite review of new drugs that demonstrate potential for addressing unmet medical need in serious or life threatening conditions. The purpose of the FDA program is to provide important drugs to the patient earlier. Under a separate FDA initiative, DARA has submitted a request for orphan drug designation for treatment of patients with painful CCIPN. Orphan designation provides extended market exclusivity, tax benefits, and waiver of PDUFA fees.
In addition to DARA’s primary development program for painful CCIPN, a sub-category of neuropathic pain that is particularly devastating to patients that have been treated with powerful and life-saving chemotherapeutic agents, a Clinical Trial Agreement with NCI provides an opportunity to collaborate on secondary exploratory studies that would focus on additional aspects of painful and chronic CIPN.
DARA is a specialty pharmaceutical company focused on the development and commercialization of oncology treatment and supportive care products. DARA holds the exclusive U.S. marketing rights to Soltamox®, a novel oral liquid formulation of tamoxifen citrate, which is widely used in the treatment and prevention of breast cancer. Soltamox is the only FDA-approved oral liquid version of tamoxifen. DARA has exclusive U.S. rights to Soltamox through a license from Rosemont Pharmaceuticals, Ltd.
In September 2012, DARA entered into an exclusive agreement with the Helsinn Group of Switzerland for U.S. commercial rights to Gelclair®, an FDA-cleared product for the treatment of oral mucositis.
Additionally, in June 2012, DARA launched its first product, Bionect®, a topical treatment for skin irritation and burns associated with radiation therapy. DARA has rights to market Bionect in the US oncology/radiology markets under license from Innocutis.
DARA is currently developing a cancer-support therapeutic compound, KRN5500, for the treatment of painful chronic chemotherapy induced peripheral neuropathy (CCIPN) in patients with cancer. This product is an excellent fit with DARA’s strategic oncology focus. KRN5500 has successfully completed a Phase 2a clinical trial, and has been designated a Fast Track Drug by the United States Food and Drug Administration. DARA is working with the National Cancer Institute (NCI) to design an additional clinical trial under joint DARA-NCI auspices while continuing further Phase 2 development. DARA is currently seeking a development and commercialization partner for KRN5500.
We have an intellectual property estate generated by license agreements as well as internal development. The patents granted related to each of our commercial products and development-stage programs is shown in the following table.
Product / Program | Intellectual Property |
Soltamox® | US Patent 6,127,425 licensed from Rosemont Pharmaceuticals, Inc. |
Gelclair® | US Patent 6,828,308 licensed from Helsinn. |
Bionect® | US Patent 5,925,626 licensed from Innocutis. |
KRN5500 Program | US Patents 5,905,069, 7,196,071, 7,375,094, 7,632,82 and related foreign patents licensed from Massachusetts General Hospital. Additional provisional and non-provisional patent applications pending (internal development). |
DB959 Program | US Patents 6,828,335, 7,476,742, 7,714,004, 7,906,653, 7,592,361, 7,964,622 and related foreign patents licensed from Bayer Pharmaceuticals. Additional non-provisional patent applications pending (licensed subject matter and internal development). |
DARA has comprehensive commercial coverage across the national oncology market through a series of agreements with a number of specialty pharmacy providers, leading group purchasing organizations (GPOs), retail partners, reimbursement experts, and an industry-leading third-party logistics provider. As part of an integrated national network with annual sales of over $1 billion in cancer therapeutics, DARA has significant commercial scale and capabilities. Its distribution network consists of more than 45,000 retail pharmacies, mail order pharmacies, and long-term care facilities. This provides DARA with established reimbursement and logistics expertise, as well as partnering opportunities with more than 300 sales and marketing personnel uniquely focused on oncology and oncology support products. This comprehensive network of partners is rare if not unique among companies in the oncology supportive care area and provides DARA a strong foundation for product introductions into the oncology market.
Our business development efforts are focused on actively identifying in-licensing opportunities to expand our oncology supportive care focus product portfolio. Areas of interest include anemia, cachexia, emesis, nutrition and pain.
We are actively seeking interested partners for the development and commercialization of KRN5500. KRN5500 is a non-narcotic, non-opioid, intravenously administered new chemical entity (NCE) in development for painful chronic chemotherapy induced peripheral neuropathy (CCIPN). KRN5500 has successfully completed a Phase 2a proof of concept study in patients with end-stage cancer, meeting its primary endpoint of pain reduction relative to placebo (p = 0.03).
DB959 is a PPAR-delta/gamma agonist which has been in clinical development for Type 2 diabetes. It was tested in Phase 1 clinical studies that demonstrated a good safety profile and provided strong evidence of pharmacologic activity in healthy volunteers. This program is currently available for out licensing.
If you are interested in exploring business development opportunities with DARA, please contact:
David Benharris
Vice President of Sales, Marketing & Business Development
919-861-0158
dbenharris@darabio.com
DARA has implemented a targeted and focused commercial approach to effectively reach oncologists in the United States. The primary strategy is to deploy a team of experienced Regional Business Directors (“RBD’s”) that have significant experience in all commercial aspects of the niche pharmaceutical industry, targeting the high prescribing oncologists. The RBD’s team affords DARA coverage across the US. In addition, strategic partnerships with specialty pharmacy groups will allow significantly increased reach and frequency to key customers, both physicians and patients.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |